Dopamine modulation of emotional processing in cortical and subcortical neural circuits: Evidence for a final common pathway in schizophrenia?

Schizophrenia Bulletin

Volumn 33, Issue 4, 2007, Pages 971-981

  Laviolette, Steven R ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Amygdala; Dopamine; Emotion; Emotional learning; Memory; Prefrontal cortex; Sensitization; Ventral tegmental area

Indexed keywords

DOPAMINE; NEUROTRANSMITTER;

ACCURACY; AMYGDALOID NUCLEUS; BRAIN CORTEX; BRAIN REGION; COGNITION; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; ELECTROPHYSIOLOGY; EMOTION; HUMAN; LEARNING; LIMBIC SYSTEM; NEUROIMAGING; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PERCEPTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY CORTEX; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VENTRAL TEGMENTUM;

AFFECT; AMYGDALA; COGNITION DISORDERS; DOPAMINE; HUMANS; LEARNING; MOTIVATION; NERVE NET; NEURAL PATHWAYS; NEURONAL PLASTICITY; PREFRONTAL CORTEX; SCHIZOPHRENIA; VENTRAL TEGMENTAL AREA;

EID: 34547672816     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm048     Document Type: Conference Paper

References (93)

1. Williamson PC. Mind, Brain, and Schizophrenia. New York, NY: Oxford University Press; 2006.
2. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res. 1997;25:1-10.
3. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5:483-494.
4. Missale C, Nash R, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189-225.
5. Wise RA. Interactions between medial prefrontal cortex and meso-limbic components of brain reward circuitry. Prog Brain Res. 2000;126:255-262.
6. Horvitz JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience. 2000;96:651-656.
7. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend. 1998;51:13-22.
8. Wise RA. Dopamine and food reward: back to the elements. Am J Physiol Regul Integr Comp Physiol. 2004;286:R13.
9. Laviolette SR, Nader K, van der Kooy D. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav Brain Res. 2002;129:17-29.
10. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci. 2004;5:55-65.
11. Grace AA. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 1995;37:111-129.
12. Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48:175-187.
13. Adolphs R, Damasio H, Tranel D, Damasio AR. Cortical systems for the recognition of emotion in facial expressions. J Neurosci. 1996;16:7678-7687.
14. Ljungberg T, Apicella P, Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol. 1992;67:145-163.
15. Becerra L, Breiter HC, Wise RA, Gonzales RG, Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron. 2001;32:927-946.
16. Volkow ND, Li TK. Drug addiction: the neurobiology of behavior gone awry. Nat Rev Neurosci. 2004;5:963-970.
17. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159:1642-1652.
18. Wang GJ, Volkow ND, Fowler JS, et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci. 1999;64:775-784.
19. Hyland BI, Reynolds JN, Hay J, Perk CG, Miller R. Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience. 2002;114:475-492.
20. Miller JD, Sanghera MK, German DC. Mesencephalic dopaminergic unit activity in the behaviorally conditioned rat. Life Sci. 1981;29:110-121.
21. Rasmussen K, Strecker RE, Jacobs BL. Single unit response of noradrenergic, serotonergic and dopaminergic neurons in freely moving cats to simple sensory stimuli. Brain Res. 1986;369:336-340.
22. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev. 1991;71:155-234.
23. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol. 1997;7:191-197.
24. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
25. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1:133-152.
26. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976;133:197-202.
27. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94:2569-2574.
28. Laruelle M, D'Souza CD, Baldwin RM, et al. Single photon emission computerized tomography imaging of amphetamineinduced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235-9240.
29. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observation. Biol Psychiatry. 1970;2:95-107.
30. Angrist BM, Sathanantham G, Wilk S, Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res. 1974;11:13-23.
31. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology. 1980;67:31-88.
32. Lieberman JA, Kane JM, Alvir JAJ. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91:415-433.
33. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997;17:205-229.
34. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci. 2006;63:1597-1613.
35. Williams LM, Phillips ML, Brammer MJ, et al. Arousal dissociates amygdala and hippocampal fear responses: evidence from simultaneous fMRI and skin conductance recording. Neuroimage. 2001;14:1070-1079.
36. Ledoux JM. Emotion: clues from the brain. Annu Rev Psychol. 1995;46:209-235.
37. Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neurosci. 2002;3:563-573.
38. Aggleton JP. The Amygdala: A Functional Analysis. 2nd ed New York, NY: Oxford University Press; 2000.
39. Feenstra MG. Dopamine and noradrenaline release in the prefrontal cortex in relation to unconditioned and conditioned stress and reward. Prog Brain Res. 2000;126:133-163.
40. Feenstra MG, Botterblom MH. Rapid sampling of extracellular dopamine in the rat prefrontal cortex during food consumption, handling and exposure to novelty. Brain Res. 1996;274:17-24.
41. Williams LM, Das P, Harris AWF, et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry. 2004;161:480-489.
42. Paradiso S, Andreasen NC, Crespo-Facorro B, et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry. 2003;160:1775-1783.
43. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 1997;349:1735-1739.
44. Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 1995;378:176-179.
45. Dolan RF, Fletcher P, Frith CD, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 1995;378:180-182.
46. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108-158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98:6917-6922.
47. Castner SA, Goldman-Rakic PS. Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry. 2003;54:105-110.
48. Lennox BR, Park SB, Medley I, Morris PG, Jones PB. The functional anatomy of auditory hallucinations in schizophrenia. Psychiatry Res. 2000;100:13-20.
49. McGuire PK, Shah GMS, Murray RM. Increased blood flow in Brocas area during auditory hallucinations in schizophrenia. Lancet. 1993;342:703-706.
50. Shergill SS, Brammer MJ, Williams SCR, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry. 2000;57:1033-1038.
51. Laviolette SR, Lipski WJ, Grace AA. A subpopulation of neurons in the medial prefrontal cortex encodes emotional learning through burst and frequency codes through a dopamine D4 receptor-dependent basolateral amygdala input. J Neurosci. 2005;25:6066-6075.
52. Laviolette SR, Grace AA. Cannabinoids dramatically potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala. J Neurosci. 2006;26:6458-6468.
53. Rosenkranz JA, Grace AA. Dopamine-mediated modulation of odor-evoked amygdala potentials during pavlovian conditioning. Nature. 2002;417:282-287.
54. Rosenkranz JA, Grace AA. The prefrontal cortex regulates lateral amygdala neuronal plasticity and responses to previously conditioned stimuli. J Neurosci. 2003;23:11054-11064.
55. Milad MR, Quirk GJ. Neurons in the medial prefrontal cortex signal memory for fear extinction. Nature. 2002;420:70-74.
56. Milad MR, Vidal-Gonzalez I, Quirk GJ. Electrical stimulation of the medial prefrontal cortex reduces conditioned fear in a temporally specific manner. Behav Neurosci. 2004;118:389-394.
57. Garcia R, Vouimba RM, Baudry M, Thompson RF. The amygdala modulates prefrontal cortex activity relative to conditioned fear. Nature. 1999;402:294-296.
58. Rosenkranz JA, Grace AA. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci. 2002;22:324-337.
59. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol. 2004;74:301-320.
60. Simon H, Le Moal M, Calas A. Efferents and afferents of the ventral tegmental-A10 region studied after local injection of [3H]leucine and horseradish peroxidase. Brain Res. 1991;178:17-40.
61. West AR, Grace AA. Frontal subcortical circuits in psychiatric and neurological disorders. In: Lichter DG, Cummings JL, eds. New York: Guilford Publications; 2001. 372-400.
62. Sesack SR, Pickel V. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens and on dopamine neurons of the ventral tegmental area. J Comp Neurol. 1992;320:145-160.
63. Nader K, LeDoux JE. The dopaminergic modulation of fear: quinpirole impairs the recall of emotional memories in rats. Behav Neurosci. 1999;113:152-165.
64. Bissiere S, Humeau Y, Luthi A. Dopamine gates LTP induction in lateral amygdala by suppressing feedforward inhibition. Nat Neurosci. 2003;6:587-592.
65. Shah AA, Sjovold T, Treit D. Selective antagonism of medial prefrontal D4 receptors decreases fear-related behaviors in rats. Eur J Neurosci. 2004;19:3392-3397.
66. Goldsmith SK, Shapiro RM, Joyce JN. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiatry. 1997;54:649-658.
67. Morrison R, Bellack A, Mueser K. Deficits in facial affect recognition and schizophrenia. Schizophr Bull. 1998;14:67-83.
68. Edwards J, Pattison PE, Jackson HJ, Wales RJ. Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res. 2001;48:235-253.
69. Mandal MK, Pandey R, Prasad AB. Facial expressions of emotions and schizophrenia: a review. Schizophr Bull. 1998;24:399-412.
70. Reynolds GP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature. 1983;305:527-529.
71. Talvick M, Norstrom AL, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol. 2003;6:361-370.
72. Talvik M, Nordstrom AL, Okubo Y, et al. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 2006;148:165-173.
73. Floresco SB, Grace A. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J Neurosci. 2003;23:3930-3943.
74. Griffith JD, Cavanuagh J, Oates J. Paranoid episodes induced by drug. JAMA. 1968;205:39.
75. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine and levamphetamine. Effects on schizophrenia symptoms. Arch Gen Psychiatry. 1976;33:304-308.
76. Kroner S, Rosenkranz JA, Grace AA, Barrionuevo G. Dopamine modulates excitability of basolateral amygdala neurons in vitro. J Neurophysiol. 2005;93:1598-1610.
77. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28:309-369.
78. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev. 1986;11:157-198.
79. Robinson TE, Berridge KC. The psychology and neurobiology of addiciton: an incentive-sensitization view. Addiction. 2000;95:(suppl 2):S91-S117.
80. A receptors in the ventral tegmental area. Nat Neurosci. 2004;7:160-169.
81. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 1993;9:67-75.
82. O'donnell P, Lewis BL, Weinberger D, Lipska BK. Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex. 2002;12:975-982.
83. Rajakumar N, Leung LS, Ma J, Rajakumar B, Rushlow W. Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle. Biol Psychiatry. 2004;55:797-803.
84. Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology. 2005;30:1426-1435.
85. Suzuki T, Ishigooka J, Watanabe S, Miyaoka T. Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats. Eur J Pharmacol. 2002;435:59-65.
86. Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S. A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Neuropsychopharmacology. 2006;32:1122-1132.
87. Paradiso S, Andreasen NC, Crespo-Facorro B, et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry. 2003;160:1775-1783.
88. Fahim C, Stip E, Mancini-Marie A, et al. Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res. 2005;140:1-15.
89. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry. 2006;59:919-928.
90. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
91. Luby ED, Gottlieb JS, Cohen BD. Model psychoses and schizophrenia. Am J Psychiatry. 1962;119:61-67.
92. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 1995;12:3-16.
93. Jentsch JD, Elsworth JD, Taylor JR, Redmond DE, Roth RH. Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia. Adv Pharmacol. 1998;42:810-824.